Cyclosporin A
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Explore 39 assets in Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive →Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
University of Michigan Rogel Cancer Center
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03842696CT.gov Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | — | Active Not Recruiting | — | — | — |
NCT01044745CT.gov Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | — | Terminated | — | — | — |
NCT00036738CT.gov Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclosporin A (this asset) | University of Michigan Rogel Cancer Center | P2 | BB · 67 |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P2 | BBB |
| Cyclophosphamide | Ohio State University Comprehensive Cancer Center | P2 | BBB |
| Imatinib | The University of Hong Kong | P2 | BB |
| Tacrolimus | University of Michigan Rogel Cancer Center | P2 | BB |
| Nilotinib | The University of Hong Kong | P2 | BB |
| Busulfanum | Fred Hutchinson Cancer Center | P2 | BB |
| Romidepsin | M.D. Anderson Cancer Center | P2 | BB |
| (+)-Vincristine | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort
Other indications for Cyclosporin A
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P3 | BBB · 76 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P3 | BBB · 76 |
| Disease Related To Transplantation | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclosporin A in Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclosporin-a-blast-phase-chronic-myelogenous-leukemia-bcr-abl1-positive
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →